Management of Decreased HDL During Testosterone Therapy

Introduction to HDL Management

The American Urological Association recommends prioritizing lifestyle modifications, such as weight loss, physical activity, and smoking cessation, as the primary intervention for low HDL during testosterone therapy, while maintaining testosterone dosing in the physiologic range (450-600 ng/dL) to minimize HDL suppression 1
The American Heart Association suggests that all men with testosterone deficiency should be counseled regarding lifestyle modifications as a treatment strategy, including weight loss and increased physical activity 1

The American Heart Association recommends weight management and physical activity as first-line interventions when HDL <40 mg/dL or triglycerides >150 mg/dL 2, 3
Target BMI of 18.5-24.9 kg/m² and waist circumference <40 inches in men, as recommended by the American Heart Association 2, 3
Minimum goal: 30-60 minutes of aerobic activity daily, or at least 3-4 times weekly, as recommended by the American Heart Association 2, 3
Aerobic exercise raises HDL levels and lowers triglyceride levels directly, according to the American Academy of Family Physicians 4
Patients who stop smoking can expect an increase of up to 30% in their HDL levels, as reported by the American Academy of Family Physicians 4

Adjust testosterone therapy dosing to achieve total testosterone levels in the middle tertile of the normal reference range (450-600 ng/dL), as recommended by the American Urological Association 1
Use minimal dosing necessary to normalize testosterone levels while improving symptoms, according to the American Urological Association 1

If HDL remains <40 mg/dL despite lifestyle modifications and optimized testosterone dosing, consider fibrate or niacin therapy, as recommended by the American Heart Association 2, 3
Fibric acids increase HDL significantly and decrease triglycerides substantially, according to the American Academy of Family Physicians 4
Nicotinic acid (niacin) provides the most potent HDL elevation and also reduces triglycerides, as reported by the American Academy of Family Physicians 4

Men on testosterone therapy should be advised to report cardiovascular symptoms during routine follow-up, as recommended by the American Urological Association 1, 5, 6
High BMI coupled with low testosterone increases cardiovascular event risk; counsel overweight/obese patients regarding weight loss programs concurrent with testosterone therapy, according to the American Urological Association 1

Testosterone therapy should not be commenced for 3-6 months in patients with recent cardiovascular events, as recommended by the American Urological Association 1, 5, 6
Do not prescribe 17-alpha-alkylated androgens (methyltestosterone) due to liver toxicity and unfavorable lipid effects, according to the American Urological Association 1, 5, 6

Physiologic testosterone replacement therapy does not worsen triglyceride levels in men with hypertriglyceridemia and appears to have a neutral to potentially beneficial effect on the overall lipid profile 7
Testosterone replacement at physiologic doses shows no significant change in triglyceride levels, as demonstrated by a dose-ranging study in 61 men receiving testosterone enanthate at doses from 25 to 600 mg weekly over 20 weeks 8
Both transdermal and intramuscular testosterone administration at replacement doses demonstrated no significant triglyceride changes in controlled trials lasting up to 36 months 9

A meta-analysis examining intramuscular testosterone esters in hypogonadal men found total cholesterol was reduced in 5 studies, increased in 2, and unchanged in 12 studies, according to the American College of Cardiology 10
LDL cholesterol remained unchanged or decreased in 14 of 15 studies analyzed, as reported by the American Heart Association 11
HDL cholesterol showed minimal changes, with reductions in only 3 studies and no change in 15 studies at physiologic doses, based on evidence from the Endocrine Society 12

Oral nonaromatizable androgenic steroids at supraphysiologic doses do adversely affect lipids, particularly lowering HDL, as noted by the American College of Cardiology 13
Standard replacement regimens, such as testosterone enanthate 100-200 mg weekly or equivalent transdermal dosing, maintain physiologic levels and avoid lipid deterioration, according to the Endocrine Society 14

Transdermal testosterone appears to have the most neutral lipid effects, with a 36-month placebo-controlled study in 108 men showing no significant differences in any lipid parameters, as reported by the American Heart Association 15
Intramuscular injections at replacement doses similarly show neutral effects, though they carry higher risk of erythrocytosis, which may indirectly affect cardiovascular risk, as noted by the American College of Cardiology 16

Baseline lipid panel is essential before initiating therapy, and recheck lipids at 3-6 months after starting therapy to confirm no worsening, as recommended by the Endocrine Society 7
Maintain testosterone levels within the normal physiologic range to avoid supraphysiologic effects, according to the American College of Cardiology 8
Monitor hematocrit more closely than lipids, as polycythemia represents a more common adverse effect that could indirectly increase cardiovascular risk, as reported by the American Heart Association 12